Lonza to biomanufacture in China with a little help from GE
Changing policies in China bring opportunities for foreign CDMOs says Lonza, which is opening a biologics facility in Guangzhou, supported by GE Healthcare. Swiss contract development and manufacturing organization(CDMO) Lonza has announced it is constructing its first biomanufacturing faci ...
Rentschler Biopharma will produce recombinant hemophilia A product Obizur for Shire after acquiring the Milford facility.
German contract deve ...
MabPlex has opened a facility in Yantai, China with up to 24,000 L of single-use capacity to serve the growth in biomanufacturing demand.
MabP ...
The US FDA has approved a second biosimilar of Roche’s breast cancer drug Herceptin (trastuzumab): Celltrion’s Herzuma, to be marketed by Tev ...
Sanofi will see its short-acting follow-on insulin Admelog be regulated as a biosimilar from 2020 under US FDA plans to promote competition. But ...
Recent Tweets
-
RT @Dan5tanton: The US FDA has approved a second biosimilar of Roche’s breast cancer drug Herceptin (trastuzumab): Celltrion’s Herz… https://t.co/hTRiMhngsJ
3 hours ago
-
#Sanofi will see short-acting follow-on insulin Admelog be regulated as a #biosimilar from 2020 under US FDA plans… https://t.co/S3c0U6OACi
3 hours ago
-
RT @Dan5tanton: Sanofi will see its short-acting follow-on insulin Admelog regulated as a biosimilar from 2020 under FDA plans to p… https://t.co/gfCnnNc6Ge
4 days ago
-
Manufacturing shutdowns and idle capacity mar #CDMO Avid’s Q2 https://t.co/HWbDM6ORD7 https://t.co/fNyGePNDmh
6 days ago
